The short version of TH9507 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Stage: as with bone sarcomas, tumors that have metastasized have a worse prognosis compared to tumors that have not metastasized. Grade: the AJCC recommends using a grading system called the French Federation of Cancer Centers Sarcoma Group (FNCLCC) Grade for soft-tissue sarcomas, with high-grade tumors having a worse prognosis compared to low-grade tumors. For GISTs, the key factor that affects prognosis is:
== Drug combination == Some ingredients such as caffeine, creatine and β-alanine are found in nearly all pre-workout blends, but each branded product is a "proprietary blend" with an average of 18 different ingredients, the exact composition and proportions of which can vary widely between different products. Additionally legal psychoactive substances occasionally used in these proprietary blends that are typically legal include 5-HTP, tyrosine, and yohimbine. Although these products are not banned, the Food and Drug Administration warns consumers to be cautious when consuming pre-workout. Benzodiazepines can cause death when mixed with other CNS depressants such as opioids, alcohol, or barbiturates. Alcohol and cocaine (for example coca wine) increase cardiovascular toxicity. Opioids or cocaine taken with ecstasy or amphetamines also result in additional acute toxicity.
== Names == The word turquoise dates to the 16th century and is derived from the Old French turquois meaning "Turkish" because the mineral was first brought to Europe through the Ottoman Empire from the mines in the historical Khorasan province of Iran (Persia). The name is considered a misnomer, as the mineral came from Persia and is not found in Turkey. The first recorded use of turquoise as a color name in English was in 1573. Pliny the Elder referred to the mineral as callais (from Ancient Greek κάλαϊς) and the Aztecs knew it as chalchihuitl. In professional mineralogy, until the mid-19th century, the scientific names kalaite or azure spar were also used, which simultaneously provided a version of the mineral origin of turquoise. However, these terms did not become widespread and gradually fell out of use.
=== Transparent conducting electrodes === Graphene's high electrical conductivity and high optical transparency make it a candidate for transparent conducting electrodes, required for such applications as touchscreens, liquid crystal displays, inorganic photovoltaics cells, organic photovoltaic cells, and organic light-emitting diodes. In particular, graphene's mechanical strength and flexibility are advantageous compared to indium tin oxide, which is brittle. Graphene films may be deposited from solution over large areas. Large-area, continuous, transparent and highly conducting few-layered graphene films were produced by chemical vapor deposition and used as anodes for application in photovoltaic devices. A power conversion efficiency (PCE) up to 1.7% was demonstrated, which is 55.2% of the PCE of a control device based on indium tin oxide. However, the main disadvantage brought by the fabrication method will be the poor substrate bondings that will eventually lead to poor cyclic stability and cause high resistivity to the electrodes. Organic light-emitting diodes (OLEDs) with graphene anodes have been demonstrated. The device was formed by solution-processed graphene on a quartz substrate. The electronic and optical performance of graphene-based devices are similar to devices made with indium tin oxide. In 2017 OLED electrodes were produced by CVD on a copper substrate.
=== EC 1.3.5 With a quinone or related compound as acceptor === EC 1.3.5.1: succinate dehydrogenase (quinone) EC 1.3.5.2: dihydroorotate dehydrogenase (quinone) EC 1.3.5.3: protoporphyrinogen IX dehydrogenase (menaquinone) EC 1.3.5.4: fumarate reductase (quinol) EC 1.3.5.5: 15-cis-phytoene desaturase EC 1.3.5.6: 9,9'-dicis-zeta-carotene desaturase
Sources: en.wikipedia.org
== Diagnosis == Joint hypermobility syndrome shares symptoms with other conditions such as Marfan syndrome and Ehlers-Danlos Syndrome. Hypermobility syndrome and Hypermobile Ehlers-Danlos syndrome are difficult to diffentiate, and the boundaries between them may be arbitrary. Hypermobility syndrome and hypermobile Ehlers-Danlos syndrome are both likely to have a variety of genetic causes. Generalized hypermobility is a common feature in hereditary connective tissue disorders and many features overlap, but often features are present that enable differentiating these disorders. Ehlers-Danlos Syndrome was defined based on its observable symptoms in the skin and joints. The inheritance pattern of Ehlers-Danlos syndrome varies by type. The arthrochalasia, classic, hypermobility and vascular forms usually have an autosomal dominant pattern of inheritance. Autosomal dominant inheritance occurs when one copy of a gene in each cell is sufficient to cause a disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new (sporadic) gene mutations. Such cases can occur in people with no history of the disorder in their family. It is impossible to tell whether a person has EDS symptoms due to an inherited EDS gene, a spontaneous mutation that causes identical symptoms, or a problem in fetal development causes identical symptoms, without both knowing the genetic family history and performing a specialized genetic test. The results do not matter to clinical treatment of the symptoms.
As of 2025, there are 3,971 known snake species worldwide, with around 600 venomous species. This is an overview of the snakes that pose a significant health risk to humans, through snakebites or other physical trauma. The varieties of snakes that most often cause serious snakebites depend on the region of the world. In Africa, the most dangerous species include black mambas, puff adders, and carpet vipers. In the Middle East, the species of greatest concern are carpet vipers and elapids; in Central and South America, Bothrops (including the terciopelo or fer-de-lance) and Crotalus (rattlesnakes) are of greatest concern. In South Asia, it has historically been believed that Indian cobras, common kraits, Russell's viper, and carpet vipers were the most dangerous species; however, other snakes may also cause significant problems in this region. While several species of snakes may cause more bodily harm than others, any one of these venomous snakes is still very capable of causing a human fatality should a bite go untreated, regardless of venom capabilities or behavioral tendencies.
=== Chemically modified dextran microspheres === Microspheres can also be developed by chemically modifying dextran. Acetated dextran can be modified with amine groups and grafted with heparin to form microspheres that provide protamine-stimulated, targeted drug release for the delivery of therapeutics to treat cardiovascular diseases. Dextran modified with an octyl- group creates microspheres that provide extended release of doxorubicin, which is an antitumor therapeutic.
As such, Hamilton argues that the focus of this teaching is on our subjective experience, not on anything external to it. Collett Cox also sees the theory of dependent origination found in the early Buddhist sources as an analysis of how suffering is produced in our experience. Cox states that it is only in later Abhidharma literature that dependent origination became an abstract theory of causation. A similar interpretation has been put forth by Bhikkhu Buddhadasa who argues that, in the list of the twelve nidanas, jati and jaramarana refer not to rebirth and physical death, but to the birth and death of our self-concept, the "emergence of the ego". According to Buddhadhasa,
Sources: en.wikipedia.org
Incandescent lights are filled with argon, to preserve the filaments at high temperature from oxidation. It is used for the specific way it ionizes and emits light, such as in plasma globes and calorimetry in experimental particle physics. Gas-discharge lamps filled with pure argon provide lilac/violet light; with argon and some mercury, blue light. Argon is also used for blue and green argon-ion lasers.
Blood factors (Factor VIII and Factor IX) Thrombolytic agents (tissue plasminogen activator) Hormones (insulin, glucagon, growth hormone, gonadotrophins) Haematopoietic growth factors (Erythropoietin, colony-stimulating factors) Interferons (Interferons-α, -β, -γ) Interleukin-based products (Interleukin-2) Vaccines (Hepatitis B surface antigen) Monoclonal antibodies (Various) Additional products (tumour necrosis factor, therapeutic enzymes) Research and development investment in new medicines by the biopharmaceutical industry stood at $65.2 billion in 2008. A few examples of biologics made with recombinant DNA technology include:
Besides violating his promises at Munich, the annexation of the rest of Czechoslovakia was, unlike Hitler's previous actions, not described in Mein Kampf. After having repeatedly stated that he was interested only in pan-Germanism, the unification of ethnic Germans into one Reich, Germany had now conquered seven million Czechs. Hitler's proclamation creating the protectorate on 16 March claimed that "Bohemia and Moravia have for thousands of years belonged to the Lebensraum of the German people". British public opinion changed drastically after the invasion. Chamberlain realised that the Munich Agreement had meant nothing to Hitler. Chamberlain told the British public on 17 March during a speech in Birmingham that Hitler was attempting "to dominate the world by force".
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.